TLR9 and melanoma: Additionally, TLR9 activation via their agonists (CpG ODN or CpG B-type oligodeoxynucleotide) and other compounds, including PF-3512767 through intralesional subcutaneous injection, have shown a protective effect in melanoma and BCCs through activating skin innate immune cells, including DCs and LCs, which activate melanoma-specific CD8+T cells and NK cells, which kill cancerous cells through their cytotoxic action (Hofmann et al., 2008[68]; Krieg, 2008[98]; Molenkamp et al., 2008[134], 2007[135]; Pashenkov et al., 2006[153]).